Heart transplantation has become a standard therapy option for advanced heart failure. The
translation of heart transplantation from innovative experiments to long-term clinical success …

Heart transplantation (HTx) has become standard treatment for selected patients with end-
stage heart failure. Improvements in immunosuppressant, donor procurement, surgical …

Despite advances in pharmacologic and device treatment of chronic heart failure, long-term
morbidity and mortality remain high, and many patients progress to end-stage heart failure …

Since the first heart transplantation (HT) in 1967, survival has steadily improved. Issues
related to over-and under-immunosuppression are, however, still common following HT …

Cardiac transplantation has become an established method for end‐stage heart disease. A
calcineurin‐inhibitor (CNI)‐based regimen is the cornerstone of immunosuppressive therapy …

Renal dysfunction after heart transplantation is a frequently observed complication, in some
cases resulting in significant limitation of quality of life and reduced survival. Since the …

BACKGROUND: Proliferation signal inhibitors (PSI) facilitate reduction in calcineurin
inhibitor exposure resulting in an improvement in creatinine clearance (CrCl) in cardiac …

Background. The results from reports analyzing the occurrence of gingival overgrowth (GO)
induced by tacrolimus are controversial. In addition, the role of pharmacological and …

Proliferation signal inhibitors (PSIs), everolimus (EVL), and sirolimus are a group of
immunosuppressor agents indicated for the prevention of acute rejection in adult heart …

Sirolimus is an immunosuppressive agent increasingly used in cardiac transplant recipients
in the setting of allograft vasculopathy or worsening renal function. Recently, sirolimus has …